.Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX27_Esketamine.Esketamine .Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX27_Esketamine.Esketamine| name: | Esketamine | |
| ATC code: | N06AX27 | route: | intranasal |
| compartments: | 2 | |
| dosage: | 56 | mg |
| volume of distribution: | 709 | L |
| clearance: | 89.2 | L/h |
| other parameters in model implementation | ||
Esketamine is the S-enantiomer of ketamine, a non-competitive NMDA receptor antagonist, used for its anesthetic and rapid-acting antidepressant properties. It is currently approved (notably as a nasal spray) for treatment-resistant depression in adults.
Pharmacokinetics in healthy adult volunteers after single intranasal administration.
Kurosawa, K, et al., & Pérez-Ruixo, C (2023). Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study. Clinical pharmacology in drug development 12(4) 397–406. DOI:10.1002/cpdd.1214 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36560916
Perez-Ruixo, C, et al., & Perez-Ruixo, JJ (2021). Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clinical pharmacokinetics 60(4) 501–516. DOI:10.1007/s40262-020-00953-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33128208